what not to take with retatrutide CONSIDERING “RETA” ? PLEASE READ THIS I'm going be very direct. If you are being offered “Reta” (retatrutide) for weight loss, do it! is: • not registered Hims & Hers data Number of Vials:1 Vial LW-Digioh

what not to take with retatrutide CONSIDERING “RETA” ? PLEASE READ THIS I'm going be very direct. If you are being offered “Reta” (retatrutide) for weight loss, do it! is: • not registered Hims & Hers data Number of Vials:1 Vial LW-Digioh

Hims & Hers data shows personalized GLP-1 plans drive real weight loss, few side effects, and strong adherence to care

Proper medical oversight matters, particularly for patients with diabetes, kidney disease, history of pancreatitis, or other comorbidities

LW-Digioh

Number of Vials:1 Vial

Durability of Results: Maintenance Studies: Tirzepatide (SURMOUNT-3): Continued treatment: Additional 5.5% weight loss Stopped treatment: Regained 14% of weight Conclusion: Need ongoing treatment Semaglutide (STEP-4): Continued treatment: Maintained loss, continued losing Stopped treatment: Regained most weight Conclusion: Need ongoing treatment Phentermine: FDA-approved for 12 weeks only Weight regain after stopping is universal Not a long-term solution All Weight Loss Medications: Obesity is chronic disease Medications treat symptoms, don’t cure Stopping medication → weight regain Long-term or indefinite use necessary for sustained results Safety Profile Comparison: Discontinuation Due to Side Effects: Tirzepatide: 6.2% Semaglutide: 6.9% Liraglutide: 9.9% Naltrexone-bupropion: 25% (very high) Orlistat: 15-20% Phentermine-topiramate: 8-10% GLP-1s have excellent tolerability considering their effectiveness